COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 7 FDA records to the applicant name Illumina, Inc.. It includes 1 original PMA approval. 3 entries are PMA supplements. 3 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Aug 21, 2024 to Sep 4, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code PQP appears in 7 of the 7 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P230011, with 7 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 2 linked filings have a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 5200 Illumina Way, San Diego, CA, 92122. Recorded on P230011/S008, decision dated Sep 4, 2026.
Device categories in this collection
Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System.
Changes described in PMA records
FDA posted a decision dated 2026-09-04 for supplement S008 to PMA P230011, TruSight Oncology Comprehensive from Illumina, Inc. The decision code is OK30, and the supplement type is a 30-Day Notice. The stated reason is a process change involving manufacturer, sterilizer, packager, or supplier, and the statement describes a supplier manufacturing site change.
This notice does not represent a new approval of the whole system or a new indication. The database fields do not state which supplier, which manufacturing site, or what specific manufacturing activity changed. The device is categorized as a next generation sequencing oncology panel, somatic or germline variant detection system under product code PQP and pathology specialty.
FDA approval-order wording
a supplier manufacturing site change
Sep 4, 2026 · 30-Day NoticeFDA’s recorded scope: Approval to expand the intended use of the TruSight Oncology Comprehensive to include a companion diagnostic indication to identify RET fusions in thyroid cancer (TC) patients and RET small DNA variant mutations in medullary thyroid cancer (MTC) patients who may benefit from treatment with RETEVMO (selpercatinib).
Aug 14, 2026 · Panel TrackFDA’s recorded scope: TruSight Oncology Comprehensive is a qualitative in vitro diagnostic test that uses targeted next-generation sequencing to detect variants in 517 genes using nucleic acids extracted from formalin-fixed, paraffin embedded (FFPE) tumor tissue samples from cancer patients with solid malignant neoplasms using the Illumina NextSeq 550Dx instrument. The test can be used to detect single nucleotide variants, multi- nucleotide variants, insertions, and deletions from DNA, and fusions in 24 genes and splice variants in one gene from RNA. The test also reports a Tumor Mutational Burden (TMB) score and Microsatellite Instability (MSI) status. The test is intended to be used as a companion diagnostic to identify cancer patients who may benefit from treatment with the targeted therapies listed in Table 1, in accordance with the approved therapeutic product labeling. In addition, the test is intended to provide tumor profiling information for use by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms. Genomic findings other than those listed in Table 1 of the intended use statement are not conclusive or prescriptive for labeled use of any specific therapeutic product.
Jun 26, 2026 · Normal 180 Day TrackFDA’s recorded scope: Labeling changes updating troubleshooting instructions.
Apr 23, 2026 · Real-Time ProcessFDA’s recorded scope: manufacturing process changes
Sep 19, 2025 · 30-Day NoticeSubsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.